Format

Send to

Choose Destination
Sci Transl Med. 2012 May 16;4(134):134ps11. doi: 10.1126/scitranslmed.3003572.

Drug-based optical agents: infiltrating clinics at lower risk.

Author information

1
Oncology Research, Roche Diagnostics GmbH, Penzberg 82377, Germany.

Erratum in

  • Sci Transl Med. 2012 Jun 13;4(138):138er3.

Abstract

Fluorescent agents with specificity to cellular and subcellular moieties present promise for enhancing diagnostics and theranostics, yet challenges associated with regulatory approvals of experimental agents stifle the clinical translation. As a result, targeted fluorescent agents have remained predominantly as preclinical imaging tools. We discuss the potential of using optically labeled drugs to accelerate the clinical acceptance of optical and optoacoustic agents, in analogy to nuclear medicine approaches. This strategy, corroborated with microdosing studies, outlines a promising approach for overcoming bottlenecks and advancing photonic clinical imaging.

PMID:
22593172
DOI:
10.1126/scitranslmed.3003572
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center